Risk of the “Androgen Deprivation Syndrome” in Men Receiving Androgen Deprivation for Prostate Cancer
Author(s) -
Vahakn B. Shahinian,
YongFang Kuo,
Jean L. Freeman,
James S. Goodwin
Publication year - 2006
Publication title -
archives of internal medicine
Language(s) - English
Resource type - Journals
eISSN - 1538-3679
pISSN - 0003-9926
DOI - 10.1001/archinte.166.4.465
Subject(s) - androgen deprivation therapy , prostate cancer , medicine , relative risk , androgen , depression (economics) , comorbidity , confounding , epidemiology , cancer , oncology , confidence interval , hormone , economics , macroeconomics
Androgen deprivation therapy for prostate cancer has been associated with a spectrum of adverse effects, such as depression, memory difficulties, and fatigue, termed the androgen deprivation syndrome. Primary care physicians providing follow-up care for men with prostate cancer will be faced with managing these effects. We therefore sought to estimate the incidence of these effects and, by using a control group, ascertain whether these effects were related to androgen deprivation itself.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom